From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Upcoming Events

Introduction to Innovation in Medical Evidence and Development Surveillance (IMEDS): The Research Resource
Introduction to Innovation in Medical Evidence and Development Surveillance (IMEDS): The Research Resource Webinar
Record Keeping and Adverse Event Reporting
Record Keeping and Adverse Event Reporting: Medical Device Reporting, Corrections and Removals and Quality System Complaint Requirements LDT Industry Education
Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub
Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub Hybrid Public Meeting: In-Person and Virtual
Biosimilar Roundtables
The Reagan-Udall Foundation for the FDA will be conducting a series of six closed-door virtual roundtable conversations with biosimilar developers to explore emerging areas of regulatory science and to create a space for active discussion and exploration between FDA and biosimilar developers.
Virtual Public Meeting on FDA's Final Rule on Requirements for Additional Traceability Records for Certain Foods
Join us on October 7 to hear insights on the Final Rule on Requirements for Additional Traceability Records from both FDA leadership and other experts from across food industry sectors.

Past Events

Advancing Treatments for Post-Traumatic Stress Disorder
The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on PTSD, convened “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.
Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
The Reagan-Udall Foundation for the FDA, in collaboration with the Bill & Melinda Gates Foundation, will host a hybrid public workshop on "Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence."
-
Online Controlled Substances Summit
The Food and Drug Administration (FDA) and the Reagan-Udall Foundation for the FDA convened the fifth Online Controlled Substances Summit.
Implementing the RAISE Action Framework
Implementing the RAISE Action Framework Webinar July 16, 2024 | 2-3pm (eastern)  
Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest
The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."
Real-World Evidence Webinar Series: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).
Natural History Studies and Registries in the Development of Rare Disease Treatments
The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.
2024 Annual Public Meeting
Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the U.S. Food and Drug Administration.
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
-
Advancing Psychedelic Clinical Study Design
Advancing Psychedelic Clinical Study Design Virtual Public Meeting Day 1: January 31, 2024 | 10am-2pm (eastern)